Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
Ann Gen Psychiatry. 2013 Jan 24;12(1):1. doi: 10.1186/1744-859X-12-1.
While indicated for schizophrenia and acute mania, ziprasidone's evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success.
虽然利培酮被批准用于治疗精神分裂症和急性躁狂症，但它在临床实践中的应用范围超出了这些监管批准的范围。我们是一个由 3 名专家组成的特邀小组，在一个工作组的领导下，对利培酮在其各种临床应用中的疗效、耐受性和安全性进行了严格的评估。制造商没有机会对审查内容提出意见。不出所料，利培酮在其指定用途上被证明是有效的，尽管它在躁狂症和混合状态中的效用缺乏对照数据。除此之外，现有数据要么不令人印象深刻，要么缺乏。一个吸引人的特点是它对体重没有影响，从而为患者提供了一种非肥胖的长期治疗选择。实践中的主要挑战包括需要在饱腹时进行给药，并管理其早期出现的不安副作用。解决这些问题对于其长期成功至关重要。
